GlassScriptPhysician profile
Sydney Domanowski
NPI 1093194631
$11,074.61
in general payments reported to CMS, 2019-2025
37 companies · $1,627 in 2025
The $1,627 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $222 · 2020: $908 · 2021: $2,768 · 2022: $2,234 · 2023: $1,294 · 2024: $2,022 · 2025: $1,627.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,926 · Education: $15.92.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,926.35 |
| Education | $15.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,510.81 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Esperion Therapeutics, INC. | $1,474.31 | 2020-2025 | Nexletol |
| Astrazeneca Pharmaceuticals LP | $1,426.37 | 2020-2025 | Farxiga, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $1,366.23 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Novo Nordisk INC | $853.47 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $553.91 | 2020-2025 | Repatha, Otezla, Evenity |
| Pfizer INC. | $512.94 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $396.77 | 2019-2025 | Jardiance |
| Biohaven Pharmaceuticals, INC. | $369.52 | 2021 | |
| Novartis Pharmaceuticals Corporation | $368.51 | 2020-2025 | |
| Teva Pharmaceuticals USA, INC. | $292.12 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $213.96 | 2021-2025 | Gardasil 9, Capvaxive, Enflonsia |
| Mylan Specialty L.P. | $213.84 | 2021-2024 | Yupelri |
| Exact Sciences Corporation | $189.54 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Biohaven Pharmaceutical Holding Company LTD. | $173.02 | 2022 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $168.32 | 2020-2025 | Veozah |
| Viatris Specialty LLC | $163.94 | 2025 | Yupelri |
| Bayer Healthcare Pharmaceuticals INC. | $114.94 | 2022-2024 | |
| Janssen Pharmaceuticals, INC | $83.87 | 2020-2022 | |
| Abbvie INC. | $76.77 | 2023-2025 | Vraylar |
| Takeda Pharmaceuticals U.S.A., INC. | $63.70 | 2021-2025 | Trintellix |
| Daiichi Sankyo INC. | $61.55 | 2020-2022 | |
| Dexcom, INC. | $52.64 | 2025 | Dexcom G6 Transmitter |
| Gilead Sciences, INC. | $46.12 | 2021-2023 | Epclusa |
| Neurocrine Biosciences, INC. | $44.76 | 2020 | |
| Abbott Laboratories | $37.78 | 2025 | Proclaim, Freestyle Libre 3 |
| Amarin Pharma, INC. | $37.54 | 2021 | |
| Axsome Therapeutics, INC. | $36.98 | 2025 | Auvelity |
| Currax Pharmaceuticals LLC | $33.16 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $26.03 | 2025 | |
| Sanofi-Aventis U.S. LLC | $18.86 | 2022 | |
| Alk-Abello, INC | $16.49 | 2023 | Grastek, Ragwitek, Odactra |
| Genentech USA, INC. | $15.96 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $15.69 | 2023 | Eliquis |
| Lundbeck LLC | $15.66 | 2023 | Rexulti |
| Optinose US, INC. | $14.32 | 2020 | |
| Allergan, INC. | $14.21 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sydney Domanowski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.